WEST CHESTER, Ohio, Feb. 14 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the Roth Capital 19th Annual OC Conference at the Ritz Carlton in Laguna Niguel, CA on Tuesday, February 20th, at 11:00 a.m. PT.
A live Web cast and recording of the presentation will be available on the Investor Relations page of AtriCure’s Web site -- www.atricure.com. After the live Web cast, the presentation will be available on AtriCure’s Web site for 30 days.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation “AF”, a rapid, irregular quivering of the upper chambers of the heart. AF affects more than 2.5 million people in the U.S. and predisposes them to a five fold increased risk of stroke.
The FDA has cleared the AtriCure bipolar ablation system and the Isolator(TM) Synergy(TM) Bipolar Ablation System for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures but to date has not cleared or approved the systems for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure Isolator(TM) Transpolar(TM) Pen for the ablation of cardiac tissue and the evaluation of cardiac arrhythmias, but the Isolator(TM) Transpolar(TM) Pen has not been approved for the treatment of AF.
Contacts: AtriCure, Inc. Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 jpiton@atricure.com The Ruth Group Nick Laudico (investors) (646) 536-7030 nlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
AtriCure, Inc.
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer ofAtriCure, Inc., +1-513-755-4561, jpiton@atricure.com; Investors: NickLaudico, +1-646-536-7030, nlaudico@theruthgroup.com, Media: Jason Rando,+1-646-536- 7025, jrando@theruthgroup.com, both of The Ruth Group forAtriCure, Inc.
Web site: http://www.atricure.com/
